UK 'impact' startups raised £2 billion in 2021
Businesses created to tackle sustainable development goals see a 127% investment increase since 2018
Stay updated with breaking news from Compass Pathway. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Businesses created to tackle sustainable development goals see a 127% investment increase since 2018
The biotech was priced for perfection; its data wasn't.
A bill that would remove penalties for the possession, personal use and social sharing of certain natural and synthetic psychedelics in California passed the state Senate Health Committee. The bill will now be reviewed by the Senate Appropriations Committee, after which it would move to a Senate floor vote if approved. SB 519 would decriminalize psilocybin, psilocyn, DMT, ibogaine, mescaline, LSD, ketamine and MDMA while expunging the criminal records of those convicted with low-level psychedelics charges. The legislation also “sets up a working group to evaluate whether to fully legaliz...
Mind Medicine (OTC:MMEDF) and Mydecine Innovations Group Inc (OTC:MYCOF) often following its moves. After reaching an all-time high of $61.69 on Dec. 14, Compass Pathways consolidated for seven weeks before making another big push to the upside on Feb. 22. After failing to reach a new high on the push, it’s been in a sharp decline, plummeting 37% over the past six weeks. The sector may be in for a turnaround, however, as Compass Pathway’s stock is starting to flash bullish signals. The Compass Pathways Chart: On March 30 Compass Pathways broke up through the sloping downward trendline th...
Alexander_Volkov/Getty Images Atai Life Sciences, the largest private psychedelics company in the world, just raised $157 million. The fresh round of capital comes months after the company closed a record $125 million in November. CEO Florian Brand told Insider the money will be used to "double down" on the company's strategy. Just months after breaking the record for largest funding round in the psychedelics field, Atai Life Sciences has raised another $157 million to continue to develop treatments for mental illnesses like depression, addiction, and anxiety. On...